Shanghai Pharmaceuticals (02607.HK): Omeprazole Sodium Bicarbonate Dry Suspension (I) Approved for Production

Zhitong Finance APP reported that Shanghai Pharmaceuticals (02607.HK) announced that recently, Shanghai Pharmaceuticals Holding Co., Ltd. (hereinafter referred to as "the Company")s subsidiary Shanghai Xinyao Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Xinyao") received the "Drug Registration Certificate" (Certificate No.: 2026S02750) issued by the National Medical Products Administration (hereinafter referred to as "NMPA") for the Omeprazole Sodium Bicarbonate Dry Suspension (I) (hereinafter referred to as "the drug"), and the drug has been approved for production.